# Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Study · id `cardio:ct-nct01968967` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01968967](<https://clinicaltrials.gov/study/NCT01968967>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01968967

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2139 participants.

## Technical summary

Registry record NCT01968967. Randomized; quadruple masking; primary purpose treatment. Start 2013-10-29 (actual); primary completion 2016-07-05 (actual). Results posted on 2017-07-24.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2139 participants (enrolled count; ClinicalTrials.gov record NCT01968967, source copy `cardio:ctgov-nct01968967-2018-07-31`, retrieved 2026-10-31)
- Started: 2013-10-29 (actual) (ClinicalTrials.gov record NCT01968967, source copy `cardio:ctgov-nct01968967-2018-07-31`, retrieved 2026-10-31)
- Primary completion: 2016-07-05 (actual) (ClinicalTrials.gov record NCT01968967, source copy `cardio:ctgov-nct01968967-2018-07-31`, retrieved 2026-10-31)
- Completion: 2017-07-10 (actual) (ClinicalTrials.gov record NCT01968967, source copy `cardio:ctgov-nct01968967-2018-07-31`, retrieved 2026-10-31)
- Results first posted: 2017-07-24 (ClinicalTrials.gov record NCT01968967, source copy `cardio:ctgov-nct01968967-2018-07-31`, retrieved 2026-10-31)
- Countries: United States; Canada; Colombia; France; Hungary; Lithuania; Mexico; Romania; Russia; Spain; Taiwan; United Kingdom (ClinicalTrials.gov record NCT01968967, source copy `cardio:ctgov-nct01968967-2018-07-31`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01968967-2018-07-31`, retrieved 2026-10-31)

## The registry's words

- Brief title: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
- Acronym: SPIRE-LDL
- Condition: Hyperlipidemia
- Intervention (Drug): Bococizumab (PF-04950615; RN316)
- Intervention (Other): Placebo
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: d9fa72ca044844a8faa73fe34ddbafccfc7f2b733ed25e174a0eefaf1e2857ce
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
